Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

Phase 4

Completed

• Conditions: Type 2 Diabetes Mellitus
• Interventions: Drug: Oral administration of Ipragliflozin

• Registration Number: NCT02791035
• Lead Sponsor: Asan Medical Center

Brief Summary

The purpose of this study is to examine the correlation between change of HbA1c, urinary glucose excretion and other factors when ipragliflozin is added to preexisting therapy in subjects with type 2 diabetes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-05-27
• Study Start: 2016-06
• Study First Submitted QC: 2016-06-01
• Study First Posted: 2016-06-06
• Primary Completion: 2017-03
• Study Completion: 2017-03
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-03
• Last Update Posted: 2017-07-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Subject who has written informed consent
• Subjects who are diagnosed as type 2 diabetes mellitus
• Subjects who are 20 to 70 years old
• Subjects on a stable diet and exercise at least 8 weeks prior to the study participation
• Stable doses of the following medications for 8 weeks or more but, HbA1c level of 7.0 to 9.5% (Metformin, Metformin + SU, Metformin + DPP-4 inhibitor, Metformin + TZD, TZD, TZD + SU, TZD + DPP-4 inhibitor, SU, SU + DPP-4 inhibitor, DPP-4 inhibitor)

Read More

Exclusion Criteria

• Type 1 DM

• Gestational DM

• Diabetic ketoacidosis

• CKD stage 3B-5 (eGFR 45)

• Severe infection, serious trauma, or perioperative period

• Known or suspected hypersensitivity to ipragliflozin

• Symptomatic urogenital infection

• Chemotherapy or radiation therapy for malignant tumor or diagnosis of malignant tumor within 5 years (except for thyroid cancer)

• Under the therapeutic intervention and/or another clinical study using IP drug

• Hepatic disease ( 3 times of upper normal limit of AST or ALT)

• Serious voiding difficulty due to neurogenic bladder or prostate hyperplasia

• Drugs not allowed for concomitant use

  • Alpha glucosidase inhibitor or meglitinide within 60 days prior to screening
  • Insulin within 60 days prior to screening
  • Systemic steroid use (PO, IV or IM) over 2 weeks within 3 months prior to screening
  • Inhalation or pleural intracavitary injection of steroid known as having high systemic absorption rate

• GLP-1 agonist (except for exenatide) within 60 days prior to screening

• Heart failure (NYHA class III-IV) or uncontrolled arrhythmia within 6 months prior to screening

• Cardiovascular diseases (unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass graft, or percutaneous coronary intervention) within 3 months prior to screening

• Subjects who are not eligible to the study according to an investigator's decision

• Inability to read the consent form

• Pregnancy, lactation, or plan to get pregnant during the study period

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ipragliflozin	Oral administration of Ipragliflozin	Ipragliflozin 50 mg/tablet, orally, 1 tablet once daily for 12 weeks

Primary Outcome Measures

Name	Time	Method
Correlation between change of HbA1c and urinary glucose excretion	Baseline and week 12

Secondary Outcome Measures

Name	Time	Method
Change of HbA1c	Baseline and week 12
Correlation between reduction in HbA1c and various parameters (HOMA-IR, HOMA-ß, insulinogenic index)	Baseline and week 12
Correlation between increase in urinary glucose excretion and various parameters (HOMA-IR, HOMA-ß, insulinogenic index)	Baseline and week 12
Chang e of fasting glucose	Baseline and week 12
Change of waist circumference	Baseline and week 12
Percentage of subjects achieving the target HbA1c(<6.5%)	week 12

Trial Locations

Locations (1)

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of